Core Insights - Fortress Biotech received FDA approval for Emrosi, a treatment for inflammatory lesions of rosacea, marking a significant milestone for the company and its partner, Journey Medical [2][3] - The company anticipates potential FDA approvals for cosibelimab by December 28, 2024, targeting metastatic or locally advanced cutaneous squamous cell carcinoma [2][3] - Fortress reported a consolidated net revenue of $14.6 million for Q3 2024, a decrease from $34.8 million in Q3 2023, primarily from marketed dermatology products [8][9] Regulatory Updates - Emrosi (Minocycline Hydrochloride Extended-Release Capsules, 40mg) was approved by the FDA in November 2024, expected to launch in early 2025 [3] - The FDA accepted the BLA resubmission for cosibelimab in July 2024, with a PDUFA goal date set for December 28, 2024 [3] - Fortress completed the asset transfer of CUTX-101 to Sentynl Therapeutics in December 2023, with a rolling submission of the NDA expected in Q4 2024 [3] Clinical Updates - Clinical data presented in October 2024 showed Emrosi provides higher dermal concentration than doxycycline, indicating a potential clinical advantage for treating rosacea [4] - Longer-term data for cosibelimab presented in September 2024 demonstrated improved response rates over time in patients with locally advanced and metastatic cSCC [4] Financial Results - As of September 30, 2024, Fortress had consolidated cash and cash equivalents of $58.9 million, down from $80.9 million at the end of 2023 [8] - Consolidated net loss attributable to common stockholders was $(15.0) million, or $(0.76) per share, for Q3 2024, compared to a net loss of $(7.1) million, or $(0.94) per share, in Q3 2023 [9][16] - Research and development expenses totaled $9.4 million for Q3 2024, significantly lower than $20.3 million in Q3 2023 [8] Commercial Product Updates - Journey Medical reported net product revenues of $14.6 million for Q3 2024, a slight decrease from $14.9 million in Q2 2024 [6] General Corporate Updates - Fortress paused dividend payments on its Series A Preferred Stock in July 2024 to maintain financial flexibility, deferring approximately $0.7 million in monthly cash payments [7] - Fortress reduced its total debt by entering a new loan agreement with Oaktree Capital Management, receiving an initial tranche of $35 million [7]

As filed with the Securities and Exchange Commission on September 27, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTRESS BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-5157386 (State or other jurisdiction of incorporation or organization) 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (Address, including zip code, and telephone number, inclu ...

Company Overview - Fortress Biotech, Inc. is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings, and dividend and royalty revenue [2] - The company has seven marketed prescription pharmaceutical products and over 20 programs in development across six large-market areas, including oncology, rare diseases, and gene therapy [2] - Fortress operates a streamlined structure that fosters efficient drug development and leverages significant biopharmaceutical industry expertise and networks to expand its portfolio [2] Upcoming Events - Lindsay A. Rosenwald, M.D., Chairman, President, and CEO of Fortress, will participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024, at 4:15 p.m. ET, in a virtual format [1] - Fortress will also be present at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, focusing on 1x1 meetings [1] - A replay of the fireside chat from the Lytham Partners conference will be available on Fortress' website for approximately 30 days following the event [1]

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress" or "Company"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that on September 19, 2024 it entered into securities purchase agreements with healthcare focused institutional investors for the issuance and sale of 3,939,394 shares of its common stock ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1][2] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point, as stocks may lose momentum when their valuations exceed future growth potential [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Fortress Biotech (FBIO) Analysis - Fortress Biotech (FBIO) has shown a four-week price change of 6.3%, indicating growing investor interest [4] - Over the past 12 weeks, FBIO's stock has gained 12.8%, with a beta of 1.81, suggesting it moves 81% more than the market [5] - FBIO has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which typically attract more investors [7] - FBIO is trading at a Price-to-Sales ratio of 0.56, suggesting it is undervalued at 56 cents for each dollar of sales [7] Group 3: Additional Investment Opportunities - Besides FBIO, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - Zacks offers over 45 Premium Screens tailored to different investing styles, aiding in the identification of potential winning stocks [9]

分组1 - Fortress Biotech reported a quarterly loss of $0.73 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.32, and an improvement from a loss of $3.60 per share a year ago, resulting in an earnings surprise of 44.70% [1] - The company posted revenues of $14.9 million for the quarter ended June 2024, which was below the Zacks Consensus Estimate by 0.49% and a decrease from $17.39 million in the same quarter last year [2] - Fortress Biotech shares have declined approximately 41.2% year-to-date, contrasting with the S&P 500's gain of 12.1% [3] 分组2 - The earnings outlook for Fortress Biotech is mixed, with the current consensus EPS estimate for the upcoming quarter at -$1.36 on revenues of $28.21 million, and for the current fiscal year at -$5.07 on revenues of $81.22 million [7] - The Medical - Biomedical and Genetics industry, to which Fortress Biotech belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Insights - Fortress Biotech, Inc. has entered into a new loan agreement with Oaktree Capital Management for up to $50 million, which includes an initial tranche of $35 million and an additional $15 million available at Oaktree's discretion [10][11] - The new loan agreement allows Fortress to repay a prior $50 million term loan and provides improved capital flexibility with a maturity date of July 2027 [5][11] - Fortress is focused on acquiring and advancing biopharmaceutical assets to enhance long-term shareholder value, with a portfolio that includes seven marketed products and over 20 programs in development across various therapeutic areas [3][10] Company Overview - Fortress Biotech is an innovative biopharmaceutical company that aims to enhance long-term value for shareholders through product revenue, equity holdings, and dividend and royalty revenue [3][10] - The company has established partnerships with leading academic institutions and biopharmaceutical companies, including AstraZeneca and Fred Hutchinson Cancer Center, to maximize its product opportunities [3] - Fortress is actively developing its portfolio in therapeutic areas such as oncology, dermatology, and rare diseases [3] Financial and Strategic Developments - The new loan agreement is expected to provide financial flexibility for Fortress to support long-term expansion and business development activities [5][10] - Fortress anticipates receiving up to three regulatory approvals on New Drug Applications (NDAs) and Biologics License Applications (BLAs) within the next 12 months, with a potential fourth BLA filing as early as 2025 [5] - Oaktree has committed nearly $4.0 billion across 35 investments in the life sciences sector since 2020, indicating a strong partnership with Fortress [6]

A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced. While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns fo ...

Core Points - Mustang Bio, Inc. has completed a registered direct offering of 6,130,000 shares of common stock at a price of $0.41 per share, generating approximately $2.5 million in gross proceeds [1][2] - The company intends to use the net proceeds for working capital and general corporate purposes [2] - In a concurrent private placement, Mustang issued unregistered warrants to purchase an additional 6,130,000 shares at the same exercise price of $0.41 per share [1][3] Offering Details - The offering was conducted under Nasdaq rules and the shares were sold at-the-market [1] - The unregistered warrants are exercisable upon stockholder approval and will expire five years from that date [1] - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [7] Company Overview - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers [10] - The company aims to acquire rights to medical technologies through licensing or ownership, fund research and development, and bring these technologies to market [10] - Mustang has partnered with leading medical institutions to advance CAR-T therapy development [10]

Core Viewpoint - Mustang Bio, Inc. has announced a definitive agreement for the issuance and sale of 6,130,000 shares of common stock at a price of $0.41 per share, along with unregistered warrants to purchase an equal number of shares, aimed at raising approximately $2.5 million for working capital and general corporate purposes [2][5]. Group 1: Offering Details - The gross proceeds from the offering are expected to be approximately $2.5 million before deducting fees and expenses [2]. - The offering includes a registered direct offering and a concurrent private placement of unregistered warrants [5]. - The unregistered warrants will have an exercise price of $0.41 per share and will expire five years from the date of stockholder approval [6]. Group 2: Regulatory Information - The unregistered warrants and underlying shares have not been registered under the Securities Act and may not be resold in the U.S. without an effective registration statement or applicable exemption [3]. - The shares offered in the registered direct offering are being made under a "shelf" registration statement previously filed with the SEC [7]. Group 3: Company Overview - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers [9]. - The company aims to acquire rights to medical technologies, fund research and development, and partner with leading medical institutions to advance CAR-T therapies [9].